FDA Approves 2nd Alzheimer’s Drug, Despite Safety Concerns
FRIDAY, Jan. 6, 2023 (HealthDay News) — The U.S. Food and Drug Administration on Friday approved a second Alzheimer’s drug, lecanemab, despite reports of rare brain bleeds linked to use of the drug in some patients. However, the FDA pointed to the drug’s benefits, as well. “Alzheimer’s disease immeasurably incapacitatesContinue Reading